跳至主要内容
临床试验/NCT07022561
NCT07022561尚未招募不适用

Social Prescribing for Advancing Resilience in Kids (SPARK): A Pilot Study of Social Prescribing for Children and Youth Mental Health in Canada

University of Ottawa1 个研究点 分布在 1 个国家目标入组 170 人开始时间: 2025年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
170
试验地点
1
主要终点
Revised Children's Anxiety and Depression Scale

研究概览

简要总结

The goal of this clinical trial is to learn if the Social Prescription (SP) intervention helps improve mental health and wellbeing in youth. It will also assess the feasibility and acceptability of implementing SP in a community setting. The main questions it aims to answer are:

  • Is the SP intervention feasible and acceptable for youth, caregivers, and staff?
  • Does the SP intervention improve mental health outcomes, reduce stress, and increase wellbeing and social connectedness in youth?

Researchers will compare the Social Prescription (SP) intervention to an education control group to evaluate its effectiveness in improving youth mental health and wellbeing.

Participants will:

  • Be randomized to receive either the SP intervention or be placed in an education control group
  • Complete wellbeing and mental health questionnaires at the beginning of the study and again after 12 weeks
  • Participate in qualitative interviews to share their experiences after participating in SP

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
11 Years 至 17 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • •between 11-17 years of age
  • •on the waitlist for mental health services
  • •are not an immediate safety threat to themselves or others as assessed by the HEADS ED questionnaire

排除标准

  • •Children < 11 years old
  • •Adolescents > 17 years old

研究组 & 干预措施

Social prescribing intervention

Experimental

Youth randomly assigned to the social prescribing intervention group will have access to a social prescribing activity during their 12 weeks of participation.

干预措施: Social Prescribing (Behavioral)

Educational control

No Intervention

Youth randomly assigned to the educational control will not be provided a social prescribing intervention program, but they will be provided an educational booklet about the importance of connections.

结局指标

主要结局

Revised Children's Anxiety and Depression Scale

时间窗: From enrollment to end of treatment or control period at 12 weeks.

The Revised Children's Anxiety and Depression Scale (RCADS) is a self-report questionnaire that measures symptoms of anxiety and depression in children and adolescents aged 8 to 18.

Perceived Stress Scale

时间窗: From enrollment to end of treatment or control period at 12 weeks.

The Perceived Stress Scale is a widely used to help understand how different situations affect our feelings and our perceived stress.

Warwick-Edinburgh Mental Wellbeing Scale

时间窗: From enrollment to end of treatment or control period at 12 weeks

The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) was developed to enable the monitoring of mental wellbeing in the general population and the evaluation of projects, programmes and policies which aim to improve mental wellbeing.

Social Connectedness Scale

时间窗: From enrollment to end of treatment or control period at 12 weeks

The Social Connectedness Scale measures the extent to which individuals feel connected to others in their social environment.

Student Resilience Survey

时间窗: From enrollment to end of treatment or control period at 12 weeks

Student Resilience Survey measuring students' perceptions of their individual characteristics as well as protective factors embedded in the environment:

次要结局

  • Acceptability of Intervention Measure(From enrollment to end of treatment or control period at 12 weeks)
  • Intervention Appropriateness Measure(From enrollment to end of treatment or control period at 12 weeks)
  • Feasibility of Intervention Measure(From enrollment to end of treatment or control period at 12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Social Prescribing for Advancing Resilience in Kids:... | 临床试验